Phase I, Traditional 3+3, Trial of PO Sorafenib and Topotecan in Refractory or Recurrent Pediatric Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Sorafenib (Primary) ; Topotecan (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions
- 03 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 09 Nov 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.